US Patent

US8501164 — Nicotine lozenge compositions

Formulation · Assigned to GlaxoSmithKline LLC · Expires 2029-06-14 · 3y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a nicotine lozenge composition with reduced levels of buffering agents that provides optimal oral pH and prompt nicotine absorption.

USPTO Abstract

The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.

Drugs covered by this patent

nicotine-polacrilex (NICOTINE POLACRILEX)

Patent Metadata

Patent number: US8501164
Jurisdiction: US
Classification: Formulation
Expires: 2029-06-14
Drug substance claim: No
Drug product claim: Yes
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.